ClinicalTrials.gg
RecruitingNCT07791160MOSAIC-TTRUpdated Sep 15, 2026

Study of Acoramidis in Patients With Transthyretin Amyloid Cardiomyopathy

An observational study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM), sponsored by Bayer. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Bayer · Observational

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive heart disease caused by the buildup of an abnormal protein, called transthyretin (TTR), in the heart. This buildup can make it harder for the heart to pump blood and may lead to worsening symptoms over time. Acoramidis is a medicine approved for the treatment of adults with wild-type or hereditary (variant) ATTR-CM. While its benefits have been demonstrated in clinical trials, more information is needed about how it is used and how patients do in everyday medical practice.

The MOSAIC-TTR study is an observational study in France. Participants will receive acoramidis as part of their usual medical care. No experimental treatments or additional medical procedures will be required. The study will collect information directly from participating hospitals and from the Healthcare European Amyloidosis Registry (HEAR; NCT05101304). The main goal of the study is to understand how patients' quality of life, daily functioning, and overall well-being change during the first 12 months of treatment with acoramidis, using questionnaires completed by the patients themselves. The study will also collect information about the characteristics of patients receiving acoramidis, how the medicine is used in routine clinical practice, and its safety and tolerability. The information collected will help improve the understanding of ATTR-CM and may help improve the care of people living with this condition.

02

Conditions studied

  • Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be recruited from centers that are part of the French Amyloidosis Network or centers that are knowledgeable in the diagnosis and management of transthyretin amyloid cardiomyopathy (ATTR-CM). There are two complementary enrollment pathways: (i) direct recruitment within this study, and (ii) integration of data from the Healthcare Amyloidosis European Registry (HEAR), a multicenter registry maintained by reference centers (see NCT05101304), to enrich the study database.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Greater than or equal to 18 years of age
  • Established diagnosis of ATTR-CM with either wild-type TTR or a variant TTR genotype
  • Initiating treatment with acoramidis with the decision to treat having been made by the treating physician prior to study enrolment in accordance with the current French Summary of Product Characteristics (SmPC)

Exclusion criteria

Exclusion Criteria:

  • Any as listed in the local approved product information
  • Prior treatment with disease-modifying treatment (e.g., tafamidis, TTR silencers and/or depleters)
  • Participation in an trial evaluating new Investigational Medicinal Products or new Investigational Medical Device outside of routine clinical practice
  • Under legal protection (guardianship, curatorship, or other legal protection measures) or deprived of liberty by administrative or judicial decision at the time of inclusion.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Single Arm

    Patients will receive acoramidis 712 mg orally BID (twice daily)

    Drug: Acoramidis

Interventions

  • 356 mg film-coated tablets. The recommended dose is 712 mg (two tables, 356 mg) orally twice daily, corresponding to a total daily dose of 1424 mg.

    Also known as: BAY3684938, BEYONTTRA

06

What researchers measure

Primary outcomes

  1. Patient Reported Outcome Measure: Amylo-AFFECT-QOL score

    Change from baseline in Amylo-AFFECT-QOL total score

    Time frame: At 3, 6, 9, and 12 months after initiation of acoramidis

  2. Patient Reported Outcome Measure: KCCQ-23 score

    Change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ-23) total score

    Time frame: At 3, 6, 9, and 12 months after initiation of acoramidis

  3. Patient Reported Outcome Measure: EQ-5D-3L index score

    3L index score of EQ-5D Health-Related Quality of Life Questionnaire

    Time frame: At 3, 6, 9, and 12 months after initiation of acoramidis

  4. Patient Reported Outcome Measure: EQ VAS score

    Visual Analog scale score of EQ-5D Health-Related Quality of Life Questionnaire

    Time frame: At 3, 6, 9, and 12 months after initiation of acoramidis

Secondary outcomes

  1. Demographic characteristics: Age

    Age of patients initiating treatment with acoramidis

    Time frame: Before treatment with acoramidis

  2. Demographic characteristics: Sex

    Sex of patients initiating treatment with acoramidis

    Time frame: Before treatment with acoramidis

  3. Demographic characteristics: Body Mass Index

    Body Mass Index of patients initiating treatment with acoramidis

    Time frame: Before treatment with acoramidis

  4. Clinical characteristics: Time between diagnosis and treatment initiation

    Time between ATTR-CM diagnosis and treatment initiation

    Time frame: Before treatment with acoramidis

  5. Clinical characteristics: ATTR-CM diagnosis

    ATTR-CM diagnosis (genetic status including mutation type \[if applicable\], phenotype)

    Time frame: Before treatment with acoramidis

  6. Clinical characteristics: ATTR-CM manifestations

    ATTR-CM manifestations prior to treatment initiation

    Time frame: Before treatment with acoramidis

  7. Clinical characteristics: Comorbidities

    ATTR-CM-relevant comorbidities that were either ongoing at treatment initiation, or were previously managed or resolved in the 12 months prior to initiating acoramidis, as well as those that began after initiating acoramidis

    Time frame: Up to 12 months before initiation of acoramidis, and during treatment with acoramidis

  8. Clinical characteristics: Prior medication and procedures

    Prior medication taken and procedures performed up to 12 months before initiation of acoramidis

    Time frame: Up to 12 months before initiation of acoramidis

  9. Treatment patterns: Treatment duration

    Duration of treatment with acoramidis

    Time frame: During treatment with acoramidis

  10. Treatment patterns: Treatment interruptions

    Proportion of patients with temporary treatment interruptions and reason for interruption

    Time frame: During treatment with acoramidis

  11. Treatment patterns: Treatment discontinuation

    Proportion of patients with permanent treatment discontinuation and reason for discontinuation

    Time frame: During treatment with acoramidis

  12. Treatment patterns: Time to treatment discontinuation

    Time to acoramidis treatment discontinuation

    Time frame: During treatment with acoramidis

  13. Treatment patterns: Concomitant medications and procedures

    Concomitant medications taken and procedures performed during treatment with acoramidis

    Time frame: During treatment with acoramidis

  14. Safety and tolerability: Adverse events

    Adverse events (AEs) occurring during treatment with acoramidis and AEs occurring up to 6 days after the last intake of acoramidis if premature permanent treatment discontinuation

    Time frame: During treatment with acoramidis and up to 6 days after the last intake of acoramidis in case of premature permanent treatment discontinuation

07

Study locations

1 of 1 sites recruiting
  • Many locations
    Many Locations, France
    Recruiting
08

References and documents

Publications

  • Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, Grogan M, Hanna M, Hoffman J, Masri A, Maurer MS, Nativi-Nicolau J, Obici L, Poulsen SH, Rockhold F, Shah KB, Soman P, Garg J, Chiswell K, Xu H, Cao X, Lystig T, Sinha U, Fox JC; ATTRibute-CM Investigators. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2024 Jan 11;390(2):132-142. doi: 10.1056/NEJMoa2305434. PubMed 38197816 ↗
  • Reant P, Kharoubi M, Donal E, Bauer F, Bezard M, Bisson A, Bodez D, Bouchot O, Cariou E, Charron P, Costa J, Courand PY, Dagrenat C, Delelis F, Duval AJ, Eicher JC, Fraix A, Gellen B, Gueffet JP, Guijarro D, Habib G, Hagege A, Huttin O, Jaccard A, Jeanneteau J, Legallois D, Logeart D, Legrand L, Inamo J, Marguerit L, Mirailles R, Pezel T, Piriou N, Roubille F, Mouhat B, Tresorier R, Von Hunolstein JJ, Taieb C, Salvat M, Zaroui A, Lairez O, Damy T. The Healthcare Amyloidosis European Registry (HEAR): design of a national registry with a European extension strategy, and foundation of the F-CRIN GRACE network. Orphanet J Rare Dis. 2025 Oct 27;20(1):534. doi: 10.1186/s13023-025-04062-y. PubMed 41139783 ↗

Individual participant data

Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Dec 2028, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2026
First posted
Aug 27, 2026
StartActual
Sep 7, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07791160
Lead sponsor
Bayer
Collaborators
Saving Lives Matters, Heart's Foundation
Responsible party
Sponsor
First posted
Aug 27, 2026
Start date
Sep 7, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 15, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
4930300139003

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion